anticoagulation, intermediate prophylactic dose - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.09 [0.78, 1.53]< 10%1 study (1/-)30.8 %some concernnot evaluable moderatecrucial-

safety endpoints 00

Major bleeding 1.83 [0.53, 6.34]< 10%1 study (1/-)16.9 %some concernnot evaluable moderatenon important-

AE of interest endpoints 00

Thromboembolic events 1.07 [0.76, 1.49]< 10%1 study (1/-)35.2 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.